Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity

Wenru Song, Hwai Loong Kong, Heather Carpenter, Hideshi Torii, Richard Granstein, Shahin Rafii, Malcolm A.S. Moore, Ronald Crystal

Research output: Contribution to journalArticle

348 Citations (Scopus)

Abstract

Dendritic cells (DCs) are potent antigen-presenting cells that play a critical role in the initiation of antitumor immune responses. In this study, we show that genetic modifications of a murine epidermis-derived DC line and primary bone marrow-derived DCs to express a model antigen β-galactosidase (βgal) can be achieved through the use of a replication-deficient, recombinant adenovirus vector, and that the modified DCs are capable of eliciting antigen-specific, MHC-restricted CTL responses. Importantly, using a murine metastatic lung tumor model with syngeneic colon carcinoma cells expressing βgal, we show that immunization of mice with the genetically modified DC line or bone marrow DCs confers potent protection against a lethal tumor challenge, as well as suppression of preestablished tumors, resulting in a significant survival advantage. We conclude that genetic modification of DCs to express antigens that are also expressed in tumors can lead to antigen-specific, antitumor killer cells, with a concomitant resistance to tumor challenge and a decrease in the size of existing tumors.

Original languageEnglish
Pages (from-to)1247-1256
Number of pages10
JournalJournal of Experimental Medicine
Volume186
Issue number8
DOIs
Publication statusPublished - 20 Oct 1997
Externally publishedYes

Fingerprint

Adenoviridae
Dendritic Cells
Immunity
Complementary DNA
Antigens
Galactosidases
Neoplasms
Therapeutics
Cell Line
Antigen-Presenting Cells
Epidermis
Bone Marrow Cells
Immunization
Colon
Bone Marrow
Carcinoma
Lung

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. / Song, Wenru; Kong, Hwai Loong; Carpenter, Heather; Torii, Hideshi; Granstein, Richard; Rafii, Shahin; Moore, Malcolm A.S.; Crystal, Ronald.

In: Journal of Experimental Medicine, Vol. 186, No. 8, 20.10.1997, p. 1247-1256.

Research output: Contribution to journalArticle

Song, Wenru ; Kong, Hwai Loong ; Carpenter, Heather ; Torii, Hideshi ; Granstein, Richard ; Rafii, Shahin ; Moore, Malcolm A.S. ; Crystal, Ronald. / Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. In: Journal of Experimental Medicine. 1997 ; Vol. 186, No. 8. pp. 1247-1256.
@article{b7f9f49c2cea4aa894603f79c485e031,
title = "Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity",
abstract = "Dendritic cells (DCs) are potent antigen-presenting cells that play a critical role in the initiation of antitumor immune responses. In this study, we show that genetic modifications of a murine epidermis-derived DC line and primary bone marrow-derived DCs to express a model antigen β-galactosidase (βgal) can be achieved through the use of a replication-deficient, recombinant adenovirus vector, and that the modified DCs are capable of eliciting antigen-specific, MHC-restricted CTL responses. Importantly, using a murine metastatic lung tumor model with syngeneic colon carcinoma cells expressing βgal, we show that immunization of mice with the genetically modified DC line or bone marrow DCs confers potent protection against a lethal tumor challenge, as well as suppression of preestablished tumors, resulting in a significant survival advantage. We conclude that genetic modification of DCs to express antigens that are also expressed in tumors can lead to antigen-specific, antitumor killer cells, with a concomitant resistance to tumor challenge and a decrease in the size of existing tumors.",
author = "Wenru Song and Kong, {Hwai Loong} and Heather Carpenter and Hideshi Torii and Richard Granstein and Shahin Rafii and Moore, {Malcolm A.S.} and Ronald Crystal",
year = "1997",
month = "10",
day = "20",
doi = "10.1084/jem.186.8.1247",
language = "English",
volume = "186",
pages = "1247--1256",
journal = "Journal of Experimental Medicine",
issn = "0022-1007",
publisher = "Rockefeller University Press",
number = "8",

}

TY - JOUR

T1 - Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity

AU - Song, Wenru

AU - Kong, Hwai Loong

AU - Carpenter, Heather

AU - Torii, Hideshi

AU - Granstein, Richard

AU - Rafii, Shahin

AU - Moore, Malcolm A.S.

AU - Crystal, Ronald

PY - 1997/10/20

Y1 - 1997/10/20

N2 - Dendritic cells (DCs) are potent antigen-presenting cells that play a critical role in the initiation of antitumor immune responses. In this study, we show that genetic modifications of a murine epidermis-derived DC line and primary bone marrow-derived DCs to express a model antigen β-galactosidase (βgal) can be achieved through the use of a replication-deficient, recombinant adenovirus vector, and that the modified DCs are capable of eliciting antigen-specific, MHC-restricted CTL responses. Importantly, using a murine metastatic lung tumor model with syngeneic colon carcinoma cells expressing βgal, we show that immunization of mice with the genetically modified DC line or bone marrow DCs confers potent protection against a lethal tumor challenge, as well as suppression of preestablished tumors, resulting in a significant survival advantage. We conclude that genetic modification of DCs to express antigens that are also expressed in tumors can lead to antigen-specific, antitumor killer cells, with a concomitant resistance to tumor challenge and a decrease in the size of existing tumors.

AB - Dendritic cells (DCs) are potent antigen-presenting cells that play a critical role in the initiation of antitumor immune responses. In this study, we show that genetic modifications of a murine epidermis-derived DC line and primary bone marrow-derived DCs to express a model antigen β-galactosidase (βgal) can be achieved through the use of a replication-deficient, recombinant adenovirus vector, and that the modified DCs are capable of eliciting antigen-specific, MHC-restricted CTL responses. Importantly, using a murine metastatic lung tumor model with syngeneic colon carcinoma cells expressing βgal, we show that immunization of mice with the genetically modified DC line or bone marrow DCs confers potent protection against a lethal tumor challenge, as well as suppression of preestablished tumors, resulting in a significant survival advantage. We conclude that genetic modification of DCs to express antigens that are also expressed in tumors can lead to antigen-specific, antitumor killer cells, with a concomitant resistance to tumor challenge and a decrease in the size of existing tumors.

UR - http://www.scopus.com/inward/record.url?scp=0030856119&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030856119&partnerID=8YFLogxK

U2 - 10.1084/jem.186.8.1247

DO - 10.1084/jem.186.8.1247

M3 - Article

VL - 186

SP - 1247

EP - 1256

JO - Journal of Experimental Medicine

JF - Journal of Experimental Medicine

SN - 0022-1007

IS - 8

ER -